Previous phase II clinical trials with β3-AR agonists demonstrated improved glucose tolerance, increased FA oxidation, and resting metabolic rate, but none of them eventually passed the trials and achieved the approval for the treatment of obesity [45–48]. This evidence concerns the gene ADRB3 and obesity disorder.